RAPID Reserve Act
Sponsored By: Senator Gary Peters
Introduced
Summary
This bill would create a rolling reserve program to build six‑month domestic reserves of critical drugs and their active pharmaceutical ingredients (APIs) to shore up vulnerable supply chains and prevent shortages during emergencies. It authorizes contracts and awards to eligible manufacturers and partners to hold, replenish, and, when needed, transfer those reserves under HHS direction.
Show full summary
- Manufacturers and distributors would have to maintain a six‑month reserve of APIs and finished drug products at registered domestic or OECD facilities and replenish those stocks with recently manufactured material. They must also agree to produce drugs or transfer API to other makers if supply gaps arise.
- Patients and health systems would gain a steadier supply of drugs judged critical for public health emergencies or at‑risk populations, reducing the chance that shortages interrupt care. The bill targets drugs with “vulnerable supply chains.”
- Federal preparedness and domestic manufacturing would get new tools. HHS must publish the list of covered drugs, issue guidance within 180 days, prefer domestic sourcing when awarding contracts, and may fund construction or renovation to boost surge capacity.
*If enacted, it would authorize $500 million for FY2026 to carry out the program, increasing federal spending.*
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Backup supply of critical medicines
This bill would create a national rolling reserve program at HHS for critical drugs and their active ingredients. HHS would award contracts to companies to make, test, store, and ship these drugs. Awarded companies would need to hold about a six-month supply of APIs and finished product in U.S. or OECD facilities. They would have to keep supplies recently made and replenish them. HHS could direct production, order transfers of API to other makers, and allocate reserves in emergencies. HHS must publish the list of covered drugs and issue guidance within 180 days. HHS would report to Congress two years after the first award and every two years after. The bill would authorize $500 million for fiscal year 2026 to carry out the program. This authorization would set a ceiling but would not actually provide the money.
Free Policy Watch
You just read the policy. Now see what it costs you.
Pick a topic. PRIA runs your household against live legislation and sends you a free personalized readout.
Pick a topic to get started
Sponsors & CoSponsors
Sponsor
Gary Peters
MI • D
Cosponsors
Sen. Blackburn, Marsha [R-TN]
TN • R
Sponsored 6/12/2025
Sen. Budd, Ted [R-NC]
NC • R
Sponsored 6/12/2025
Sen. Kaine, Tim [D-VA]
VA • D
Sponsored 6/12/2025
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govTake It Personal
Get Your Personalized Policy View
Take the PRIA Score to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in